Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 706-710, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.706-710.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Biological Response Modifier Activity of an
Exopolysaccharide from Paenibacillus jamilae CP-7
Alfonso
Ruiz-Bravo,*
Maria
Jimenez-Valera,
Encarnacion
Moreno,
Victor
Guerra, and
Alberto
Ramos-Cormenzana
Department of Microbiology, Faculty of
Pharmacy, University of Granada, Granada, Spain
Received 26 July 2000/Returned for modification 6 December
2000/Accepted 21 March 2001
 |
ABSTRACT |
An extracellular polysaccharide was purified from culture
supernatants of Paenibacillus jamilae CP-7, a gram-positive
bacillus that was isolated from compost prepared with olive mill
wastewaters. The extracellular polysaccharide was produced under
aerobic conditions in a medium containing olive mill wastewaters (80%
[vol/vol]). This exopolymer had a low level of acute toxicity when it
is administered to BALB/c mice by the intraperitoneal route.
Interesting immunomodulatory effects were detected when mice were given
10 mg of exopolysaccharide per kg of body weight; the proliferative
responses of splenocytes to B-cell and T-cell mitogens were suppressed,
the in vitro levels of production of gamma interferon and
granulocyte-macrophage colony-stimulating factor by unstimulated and
lipopolysaccharide-stimulated splenocytes were enhanced, and the levels
of resistance to the intracellular pathogen Listeria
monocytogenes was increased in mice. Also, the exopolysaccharide
was able to induce lymphocyte proliferation in vitro. We conclude that
P. jamilae produces an exopolysaccharide with interesting
immunomodulatory properties.
 |
INTRODUCTION |
Microbial exopolysaccharides (EPSs)
often show clearly identified properties that form the basis for a wide
range of applications in food, pharmaceutical, petroleum, and other
industries (32). Thus, several EPSs have been shown to
possess immunological activities with potential pharmacological
applications as biological response modifiers (BRMs). BRMs are agents
that alter the normal immune response and whose mechanisms of action
include induction of cytokines (29). Research on
pharmacological applications of BRMs has led to development of both
immunosuppressive and immunostimulating drugs that are effective in
preventing the rejection of transplanted organs, for the treatment of
some autoimmune diseases, as cancer immunotherapy, or as adjuvants for
vaccine construction (14). Lentinan and other fungal
glucans, yeast mannan fractions, and a number of bacterial EPSs have
been identified as BRMs and have been found to have the ability to
stimulate tumor rejection (for a review, see reference
40). In recent years, research has focused on the
mechanisms of action of these compounds (12, 41), as well
as on the discovery of new ones (7, 33).
Although polysaccharides are considered to be T-cell-independent
antigens, a number of microbial EPSs are immunomodulators, with
activities for T cells and macrophages (for a review, see reference
35). Polysaccharide A, a component of the capsular complex
of Bacteroides fragilis, possesses mitogenic activity for T
lymphocytes (6), and the production of interleukin-2 (IL-2) by CD4+ T cells appears to play an essential role in
the in vivo immunomodulation by this EPS (37). A number of
fungi and yeasts produce
-(1,3)-glucans with immunomodulatory
properties (4, 35). Studies on the mechanisms of
immunomodulation by a soluble derivative of
-(1,3)-glucan have shown
that it has the ability to prime granulocytes and macrophages for
enhanced cytokine release (30), reactive nitrogen
intermediate production (11), and bactericidal capacity
(39) in response to a secondary stimulus. In addition,
this polymer modulates cytokine production by lymphocytes
(31). Other levels of the immune response may be
also affected by polysaccharides: mannuronan, an EPS from Pseudomonas aeruginosa, enhances natural cytotoxicity by
increasing Fas ligand expression in NK cells (17). As a
consequence of their BRM properties, a number of EPSs are able to
induce resistance to bacterial infections in experimental models
(20, 36), and some of them have been evaluated in clinical
trials (3).
In the investigation described here, an EPS was purified from culture
supernatants of a Paenibacillus jamilae strain growing on
olive mill wastewaters under aerobic conditions, and the BRM properties
of this EPS were evaluated.
 |
MATERIALS AND METHODS |
Production and isolation of EPSs.
Strain CP-7 was isolated
from compost prepared with olive mill wastewaters and was identified as
P. jamilae on the basis of phenotypic and phylogenetic
analyses and DNA-DNA relatedness studies (1). The growth
medium for seed cultures contained olive mill wastewaters (80%
[vol/vol]), NH4Cl (0.1% [wt/vol]), and yeast extract
(0.1% [wt/vol]); and the pH was adjusted to 7.0 before sterilization
by autoclaving at 112°C. Bacteria were grown in this medium at 30°C
for 48 h, and 10 ml of seed culture was transferred to a 300-ml
preculture flask containing 90 ml of the same medium. The flasks were
incubated on a shaker (120 rpm) at 30°C for 48 h, and each
culture (100 ml) was used as an inoculum for 900 ml of a culture medium
containing olive mill wastewaters (80% [vol/vol]) and
NH4Cl (0.1% [wt/vol]). EPS was produced by bacteria
during incubation at 30°C for 72 h in a 2.0-liter jar-fermentor
(Biostat M; Braun-Biotech, Melsungen AG, Germany), with aereation
provided by bubbling (850 ml/min) and agitation at 150 rpm. Bacterial
cells were separated from the fermented broth by centrifugation, and the EPS present in the supernatant was precipitated by the addition of
2 volumes of cold ethanol. The precipitated material was collected by
centrifugation, dissolved in distilled water, and dialyzed against
distilled water. The EPS was purified by chromatography on a column of
Sepharose CL-2B and elution with 50 mM phosphate (pH 7.0) containing
0.5 M NaCl. Carbohydrates and proteins were determined in the eluted
fractions by the methods of Dubois et al. (13) and
Bradford (5), respectively. The elution profile showed two
EPS fractions with molecular masses of 500 kDa and >2,000 kDa,
respectively. The light fraction showed a high carbohydrate/protein ratio and represented about 40% of the total EPS, whereas the heavy
fraction contained only sugars and represented about 60% of the total EPS.
Mouse treatment.
Six- to 8-week-old female BALB/c mice were
provided by Technical Services of the University of Granada (Granada,
Spain). They were maintained under pathogen-free conditions. EPS was
dispersed at the desired doses in pyrogen-free water, and each mouse
received one injection (200 µl per 20 g of body weight) by the
intraperitoneal route.
Mouse toxicity test.
Mice were weighed and injected
intraperitoneally with pyrogen-free water (control group) and several
EPS doses (treated groups). Following injection, the mice were observed
and their body weights were recorded daily for 10 days. The mice were
killed on day 10 after injection, and the spleens were removed and
weighed. Splenic index was expressed as the spleen weight (in grams)
per 20 g of body weight.
Spleen cell proliferation assay.
The spleens were removed
aseptically and homogenized in Hanks' balanced salt solution (Sigma
Chemical Co, St. Louis, Mo.). Splenocytes were sedimented by
centrifugation; resuspended in red blood cell lysing buffer (Sigma) for
10 min; washed; and resuspended in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum, 50 µM 2-mercaptoethanol,
penicillin G (100 U/ml), streptomycin (100 µg/ml), amphotericin B
(0.25 µg/ml), 1 mM sodium pyruvate, and 2 mM L-glutamine
(Sigma). Cell suspensions were distributed (5 × 105
viable cells per well) into 96-well tissue culture clusters with flat-bottom wells (Costar, Cambridge, Mass.). Salmonella
enterica serovar Typhi lipopolysaccharide (LPS; Sigma) was used at
2.5 µg/ml as the B-cell mitogen, and concanavalin A (ConA; Sigma) was
used at 1 µg/ml as the T-cell mitogen; these mitogen concentrations have been shown to induce optimum splenocyte proliferation under our
assay conditions (18). After incubation at 37°C in 5%
CO2 for 3 days, proliferation of spleen cells was measured
by colorimetric reading of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction
as described by Mosmann (23).
Cytokine assays.
Spleen cells were cultured with LPS or ConA
as described above, and supernatants were removed after 24 h for
determination of IL-2 levels and after 72 h for determination of gamma
interferon (IFN-
) and granulocyte-macrophage colony-stimulating
factor (GM-CSF) levels. Supernatants were stored at
20°C until they
were assayed. Cytokines were quantified by enzyme immunoassays
(Endogen, Cambridge, Mass.); the concentrations of IL-2, IFN-
, and
GM-CSF were interpolated from the standard curve for the appropriate
recombinant cytokine.
Challenge with Listeria monocytogenes.
A
virulent isolate of L. monocytogenes was kindly provided by
M. De La Rosa (Hospital Virgen de las Nieves, Granada, Spain). Bacteria
were grown on blood agar at 37°C for 24 h, harvested in sterile
phosphate-buffered saline (PBS) solution, washed twice, and resuspended
in PBS. The bacteria were counted by using a Petroff-Hausser chamber,
and the bacterial suspension was adjusted to inject 103
organisms into a mouse tail vein. The mice were observed daily, and
deaths were recorded.
Statistical analysis.
The differences between the treated
and the control groups were analyzed by using Student's t
test. A P value of less than 0.05 was considered significant.
 |
RESULTS |
EPS production.
The culture conditions used in the present
study were determined in previous work as appropriate to obtain the
maximal level of EPS production (26). After 72 h of
incubation, the EPS yield was 5.5 g/liter. EPS was obtained as a
water-soluble, white powder.
EPS toxicity.
In the acute toxicity tests, no mortality was
observed after intraperitoneal administration of 100, 10, and 1 mg of
EPS per kg of body weight (data not shown). Mice that received 100 mg/kg showed a significant decrease in body weight at the first day after injection (P < 0.0001), but this effect
dissapeared on the second day (Fig. 1).
When these animals were killed at 10 days after injection, significant
splenomegaly was observed. For EPS dosages of 0, 1, 10, and 100 mg/kg
of body weight, splenic indices (measured on day 10 after treatment and
expressed as spleen weight [in grams] per 20 g of body weight)
were 0.1016 ± 0.01024, 0.1080 ± 0.00707, 0.1072 ± 0.00563, and 0.1254 ± 0.01024 (P < 0.01), respectively (the results represent the means ± standard
deviations for five mice). Each mouse received a single injection by
the intraperitoneal route. Mice in the control group (0 mg/kg) were given sterile water. The mean values of the splenic index for treated
mice represented 123% of the splenic indices for untreated controls
(P < 0.01). No variations in body weight or
splenomegaly were observed in mice treated with EPS doses of 10 or 1 mg/kg. For in vivo immunomodulation studies, the dosage of 10 mg/kg was selected on the basis of the lack of adverse effects in toxicity tests.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of EPS on the variation of body weight of BALB/c
mice. Each mouse received a single dose of EPS by the intraperitoneal
route on day 0. Data are expressed as the mean ± standard
deviation for five mice. , no treatment; , 100 mg of EPS/kg; ,
10 mg of EPS/kg; , 1 mg of EPS/kg.
|
|
Effect of treatment with EPS on mitogen-induced responses of
splenocytes.
The capacity of splenocytes to proliferate in
response to mitogens was assayed at days 1, 4, and 7 after single-dose
EPS treatment. Results are shown in Fig.
2. EPS given 1 day before the assay suppressed 49% (P < 0.002) of the proliferation in
response to LPS and 37% (P < 0.01) of the
proliferation in response to ConA. Treatment of mice with EPS on day 4 before the assay was also suppressive: the response to LPS was
decreased by 17% (P < 0.02), although the response to
ConA was not significantly suppressed. The administration of EPS on day
7 before the test did not modify spleen cell proliferation in response
to either mitogen.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Mitogen-induced proliferation of splenocytes from
EPS-treated mice. Each mouse received a single intraperitoneal
injection of EPS (10 mg per kg of body weight) on day 0. Results are
means for five mice and are representative of two separate experiments.
Error bars represent standard deviations. , LPS; , ConA.
|
|
To determine whether the suppression of lymphoproliferative responses
observed in cultures of spleen cells from EPS-treated mice was
accompanied by changes in the production of cytokines, mice were killed
on the first day after EPS administration, and the production of IL-2,
IFN-
, and GM-CSF by unstimulated and LPS- or ConA-stimulated
splenocytes was measured in vitro. The results are shown in Fig.
3. In the absence of mitogenic stimuli, the basal levels of IFN-
and GM-CSF in cultures of splenocytes from
EPS-treated mice were higher than those in cultures of splenocytes from
untreated controls (mean increases, 1.8- and 2.2-fold, respectively, with P values of <0.05 for both cytokines). LPS did not
modify EPS-induced increases from basal levels of IFN-
and GM-CSF
production (mean increases, 2.1- and 2.0-fold, respectively, with
P values of <0.05 for both cytokines). In contrast, ConA
induced higher levels of GM-CSF secretion in untreated controls than in
EPS-treated mice (P < 0.002). The production of IL-2
by unstimulated or mitogen-stimulated splenocytes was not affected by
the treatment with EPS.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Cytokine production by splenocytes from
EPS-treated mice. Each mouse received a single intraperitoneal
injection of EPS (10 mg per kg of body weight) 1 day before the assay.
Spleen cells from control mice (open bars) and EPS-treated mice (solid
bars) were stimulated in vitro with LPS or ConA, and the cytokine
levels in the supernatants were measured by specific immunoassays.
Results are means for five mice and are representative of two separate
experiments. Error bars represent standard deviations. IFN-y,
IFN- .
|
|
Protective effect of EPS against experimental infection with
L. monocytogenes.
To determine wether EPS-induced
modifications in splenocyte responsiveness could affect cell-mediated
immunity and resistance against intracellular pathogens, mice were
challenged with a lethal inoculum of L. monocytogenes on day
1 after EPS treatment. This bacterium causes a systemic infection in
mice, and both activated T cells and macrophages are required to
overcome infection (38). As shown in Fig.
4, 80% of the EPS-treated animals
survived a challenge by the intravenous route with a dose of L. monocytogenes that was lethal for 100% of the control mice.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4.
Resistance of EPS-treated mice to L. monocytogenes. Control mice (broken line) and mice given 10 mg of
EPS per kg of body weight (solid line) were challenged by the
intravenous route with L. monocytogenes (103
organisms per mouse) on day 0 (1 day after EPS administration). The
results presented here are from one of two experiments with similar
results.
|
|
Lymphocyte-proliferating activity of EPS.
To investigate the
in vitro effect of EPS on lymphocytes, spleen cells from untreated mice
were incubated with a range of EPS concentrations: 100, 10, and 1 µg/ml. The lymphoproliferation assay was performed as decribed above.
Results from experiments that compared the mitogenic abilities of LPS,
ConA, and EPS are presented in Fig. 5. An
EPS concentration of 100 µg/ml elicited a proliferative response
representing 60 and 37% of those elicited by LPS (2.5 µg/ml) and
ConA (1 µg/ml), respectively. Little proliferation was observed at
low EPS concentrations.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
Lymphoproliferative activity of EPS. Splenocytes from
untreated mice were incubated with control mitogens (LPS and ConA) or
EPS (100, 10, and 1 µg/ml). The results are the means for three mice
(with eight replicate wells per mitogen and per mouse). Error bars
represent standard deviations.
|
|
 |
DISCUSSION |
EPS can be produced by P. jamilae strain CP-7 in a
medium containing olive oil wastewater (80%). Olive oil waste
effluents are major pollulants in the Mediterranean area and represent
a severe environmental problem because of its content of large amounts of phenolic compounds, which have antimicrobial and phytotoxic activities (9, 10, 15, 22). Ramos-Cormenzana et al.
(27) suggested that olive mill wastewater could be used as
an alternative, low-cost substrate for EPS production because of its
high carbon/nitrogen ratio, which is similar to that of standard media
used for polysaccharide production. In the study described here, an EPS
with interesting BRM properties was purified from culture supernatants
of strain CP-7 grown in an olive oil wastewater-based medium.
EPS had a low level of acute toxicity: no adverse effects were observed
in mice given a single dose of 10 mg/kg by the intraperitoneal route.
However, this treatment caused a marked immunomodulation: there was an
inhibitory effect on the proliferative responses of splenocytes to
B-cell and T-cell mitogens; the in vitro level of production of IFN-
and GM-CSF by unstimulated and LPS-stimulated splenocytes was enhanced,
and the ConA-induced level of production of GM-CSF was decreased. The
EPS-induced immunomodulation resulted in a remarkable increase in the
level of resistance to the intracellular pathogen L. monocytogenes in mice. The ability of EPS to induce lymphocyte
proliferation in vitro confirms its immunomodulatory properties.
A global picture can be proposed to describe the BRM activity of EPS.
IFN-
-activated macrophages are central to the restriction of
listerial replication (21). IFN-
stimulates macrophages to produce reactive nitrogen intermediates (16), which, in
turn, exert inhibitory effects on lymphocyte proliferation (2,
8). Thus, the increased ability of splenocytes from EPS-treated
mice to produce IFN-
is consistent with both the decrease in the
level of splenocyte proliferation in response to mitogens and the
increased level of resistance of mice to experimental listeriosis.
Several cell types may be involved in IFN-
production: NK cells,
/
T cells, and Th1 cells (19). The in vitro level of production of IFN-
by splenocytes from EPS-treated mice was not increased in cultures stimulated with ConA, suggesting that IFN-
was
not produced by T cells. Moreover, production of IL-2, which is a
typical Th1 cytokine (24), was not affected by treatment with EPS. Thus, our results indirectly indicate that NK cells may be
involved in the immunopotentiation by EPS, although further work is
required to confirm this.
Regarding GM-CSF, T cells and activated macrophages are two known
sources of this cytokine (28, 34). Since the levels of
GM-CSF in supernatants of ConA-stimulated splenocytes were decreased by
EPS treatment, it is likely that activated macrophages contributed to
increased levels of this cytokine in unstimulated or LPS-stimulated
cultures of splenocytes from EPS-treated mice. The central role of
GM-CSF in the differentiation of precursor cells into
antigen-presenting cells (25) could also be important in
the immunomodulation by EPS.
In conclusion, our results demonstrate the production of EPS with BRM
properties by P. jamilae. Additional studies on the chemical
characterization of this EPS are in progress.
 |
ACKNOWLEDGMENTS |
This work was supported by grants OLI96-2189 from Plan Nacional
de I + D and PB96-1403 from DGICYT (Ministerio de Educación y Cultura of Spain). V.G. received a grant from the Instituto de
Cooperación Iberoamericana (Agencia Española de
Cooperación Internacional of Spain).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departamento de
Microbiologia, Facultad de Farmacia, Universidad de Granada, 18071 Granada, Spain. Phone: 958-243872. Fax: 958-246235. E-mail:
aruizbr{at}platon.ugr.es.
 |
REFERENCES |
| 1.
| Aguilera, M., M. Monteoliva-Sanchez, A. Suarez, V. Guerra, C. Lizama, A. Bennasar, and A. Ramos-Cormenzana.
Paenibacillus jamilae sp. nov., an
exopolysaccharide-producing bacterium able to grow in olive-mill
wastewater. Int. J. Syst. Evol. Microbiol., in press.
|
| 2.
|
Albina, J. E.,
J. A. Abate, and W. L. Henry.
1991.
Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation.
J. Immunol.
147:144-148[Abstract].
|
| 3.
|
Babineau, T. J.,
P. Marcello,
W. Swails,
A. Kenler,
B. Bistrian, and R. A. Forse.
1994.
Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.
Ann. Surg.
220:601-609[Medline].
|
| 4.
|
Bleicher, P., and W. Mackin.
1995.
Betafectin PGG-glucan: a novel carbohydrate immunomodulator with anti-infective properties.
Annu. Rev. Pharmacol. Toxicol.
37:143-166[CrossRef][Medline].
|
| 5.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 6.
|
Brubaker, J. O.,
Q. Li,
A. O. Tzianabos,
D. L. Kasper, and R. W. Finberg.
1999.
Mitogenic activity of purified capsular polysaccharide A from Bacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro.
J. Immunol.
162:2235-2242[Abstract/Free Full Text].
|
| 7.
|
Calazans, G. M. T.,
C. E. Lopes,
R. M. O. C. Lima, and F. P. de França.
1997.
Antitumor activities of levans produced by Zymomonas mobilis strains.
Biotechnol. Lett.
19:19-21.
|
| 8.
|
Candolfi, E.,
C. A. Hunter, and J. S. Remington.
1995.
Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis.
Infect. Immun.
63:751-756[Abstract].
|
| 9.
|
Capasso, R.
1997.
The chemistry, biotechnology, and ecotoxicology of the polyphenols naturally occurring in vegetable wastes.
Curr. Top. Phytochem.
1:145-156.
|
| 10.
|
Capasso, R.,
A. Evidente,
L. Shivo,
G. Orru,
M. A. Marcialis, and G. Cristinzio.
1995.
Antibacterial polyphenols from olive oil mill wastewaters.
J. Appl. Bacteriol.
79:393-398[Medline].
|
| 11.
|
Cleary, J. A.,
G. E. Kelly, and A. J. Husband.
1999.
The effect of molecular weight and beta-1,6-linkages on priming of macrophage function in mice by (1,3)-beta-D-glucan.
Immunol. Cell Biol.
77:395-403[CrossRef][Medline].
|
| 12.
|
Donmez, C., and M. J. Groves.
1997.
Activity of mycobacterial antineoplastic glycan against human breast cancer.
Anticancer Res.
17:445-450[Medline].
|
| 13.
|
Dubois, M.,
K. A. Gilles,
J. K. Hamilton,
P. A. Rebers, and F. Smith.
1956.
Colorimetric methods for determination of sugars and related substances.
Anal. Chem.
28:350-356[CrossRef].
|
| 14.
|
Georgiev, V. S.
1993.
Immunomodulating drugs: major advances in research and development.
Ann. N. Y. Acad. Sci.
685:1-10.
|
| 15.
|
Gonzalez, M. D.,
E. Moreno,
J. Quevedo-Sarmiento, and A. Ramos-Cormenzana.
1990.
Studies on antibacterial activity of waste waters from olive oil mills (alpechin): inhibitory activity of phenolic and fatty acids.
Chemosphere
20:423-432.
|
| 16.
|
Grazzinelli, R. T.,
I. P. Oswald,
S. T. James, and A. Sher.
1992.
IL-10 inhibits parasite killing and nitrogen oxide production by IFN- -activated macrophages.
J. Immunol.
148:1792-1796[Abstract].
|
| 17.
|
Halaas, O.,
R. Vik, and T. Espevik.
1998.
Induction of Fas ligand in murine bone marrow NK cells by bacterial polysaccharides.
J. Immunol.
160:4330-4336[Abstract/Free Full Text].
|
| 18.
|
Jimenez-Valera, M.,
A. Sampedro,
E. Moreno, and A. Ruiz-Bravo.
1995.
Modification of immune response in mice by ciprofloxacin.
Antimicrobi. Agents Chemother.
39:150-154[Abstract].
|
| 19.
|
Kaufmann, S. H. E.
1993.
Immunity to intracellular bacteria, p. 1251-1286.
In
W. E. Paul (ed.), Fundamental immunology. Raven Press, New York, N.Y.
|
| 20.
|
Kernodle, D. S.,
H. Gates, and A. B. Kaiser.
1998.
Prophylactic anti-infective activity of poly-[1-6]- -D-glucopyranosyl-[1-3]- -d-glucopyranose glucan in a guinea pig model of staphylococcal wound infection.
Antimicrob. Agents Chemother.
42:545-549[Abstract/Free Full Text].
|
| 21.
|
Ladel, C. H.,
C. Blum, and S. H. E. Kaufmann.
1996.
Control of natural killer cell-mediated innate resistance against the intracellular pathogen Listeria monocytogenes by / T lymphocytes.
Infect. Immun.
64:1744-1749[Abstract].
|
| 22.
|
Moreno, E.,
J. Quevedo-Sarmiento, and A. Ramos-Cormenzana.
1990.
Antibacterial activity of waste waters of olive oil mills, p. 731-757.
In
P. N. Cheremisinoff (ed.), Encyclopedia of environmental control technology, vol. 4. Gulf Publishing, Houston, Tex.
|
| 23.
|
Mosmann, T.
1983.
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Methods
65:56-63.
|
| 24.
|
Mosmann, T. R., and R. L. Coffman.
1989.
Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol.
7:145-173[CrossRef][Medline].
|
| 25.
|
Palucka, K. A.,
N. Taquet,
F. Sanchez-Chapuis, and J. C. Gluckman.
1998.
Dendritic cells as the terminal stage of monocyte differentiation.
J. Immunol.
160:4587-4595[Abstract/Free Full Text].
|
| 26.
|
Ramos-Cormenzana, A.,
V. Guerra, and M. Monteoliva-Sanchez.
1997.
Production of microbial polysaccharides in wastewaters from olive oil mills, p. 259-262.
In
H. Verachtert, and W. Verstraete (ed.), International symposium on environmental biotechnology, part II. Technologisch Instituut, Ostend, Belgium.
|
| 27.
|
Ramos-Cormenzana, A.,
M. Monteoliva-Sanchez, and M. J. Lopez.
1995.
Bioremediation of alpechin.
Int. Biodeterion. Biodegr.
35:249-268[CrossRef].
|
| 28.
|
Rao, P.,
L. A. Falk,
S. F. Dougherty,
T. Sawada, and D. H. Pluznik.
1997.
Colchicine down-regulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages.
J. Immunol.
159:3531-3539[Abstract].
|
| 29.
|
Roth, J. A.
1988.
Enhancement of nonspecific resistance to bacterial infection by biologic response modifiers, p. 329-342.
In
J. A. Roth (ed.), Virulence mechanisms of bacterial pathogens. American Society for Microbioogy, Washington, D.C.
|
| 30.
|
Sherwood, E. R.,
D. L. Williams,
R. B. McNamee,
E. L. Jones,
I. W. Browdwe, and N. R. DiLuzio.
1987.
Enhancement of interleukin-1 and interleukin-2 production of soluble glucan.
Int. J. Immunopharmacol.
9:261-267[CrossRef][Medline].
|
| 31.
|
Soltys, J., and M. T. Quinn.
1999.
Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with -(1,6)-branched -(1,3)-glucan.
Infect. Immun.
67:244-252[Abstract/Free Full Text].
|
| 32.
|
Sutherland, I. W.
1990.
Biotechnology of microbial exopolysaccharides.
Cambridge University Press, London, United Kingdom.
|
| 33.
|
Tian, X. X.,
A. F. Li,
W. C. Zhou,
I. V. Farrugia, and M. J. Groves.
1999.
Isolation and biological activities of an antineoplastic protein-polysaccharide complex (PS4A) obtained from Mycobacterium vaccae.
Anticancer Res.
19:237-243[Medline].
|
| 34.
|
Tretter, T.,
M. J. Aman,
G. Bug,
C. Huber, and C. Peschel.
1998.
Hematopoietic growth factors are differentially regulated in monocytes and CD4(+) T lymphocytes: influence of IFN-alpha and interleukin-4.
J. Interferon Cytokine Res.
18:95-102[Medline].
|
| 35.
|
Tzianabos, A. O.
2000.
Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function.
Clin. Microbiol. Rev.
13:523-533[Abstract/Free Full Text].
|
| 36.
|
Tzianabos, A. O.,
F. C. Gibson,
R. L. Cisneros, and D. L. Kasper.
1998.
Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators.
J. Infect. Dis.
178:200-206[Medline].
|
| 37.
|
Tzianabos, A. O.,
P. R. Russell,
A. B. Onderdonk,
F. C. Gibson,
C. Cywes,
M. Chan,
R. W. Finberg, and D. L. Kasper.
1999.
IL-2 mediates protection against abscess formation in an experimental model of sepsis.
J. Immunol.
163:893-897[Abstract/Free Full Text].
|
| 38.
|
Unanue, E. R.
1997.
Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response.
Immunol. Rev.
158:11-25[CrossRef][Medline].
|
| 39.
|
Wakshull, E.,
D. Brunke-Reese,
J. Lindermuth,
L. Fisette,
R. S. Nathans,
J. J. Crowley,
J. C. Tufts,
J. Zimmerman,
W. Mackin, and D. S. Adams.
1999.
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor.
Immunopharmacology
41:89-107[CrossRef][Medline].
|
| 40.
|
Whistler, R. L.,
A. A. Bushway,
P. P. Singh,
W. Nakahara, and R. Tokuzen.
1976.
Noncytotoxic, antitumor polysaccharides.
Adv. Carbohydr. Chem. Biochem.
32:235-275[Medline].
|
| 41.
|
Yan, J.,
V. Vetvicka,
Y. Xia,
A. Coxon,
M. C. Carroll,
T. N. Mayadas, and G. D. Ross.
1999.
Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
J. Immunol.
163:3045-3052[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 706-710, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.706-710.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Leung, M.Y.K., Liu, C., Zhu, L.F., Hui, Y.Z., Yu, B., Fung, K.P.
(2004). Chemical and biological characterization of a polysaccharide biological response modifier from Aloe vera L. var. chinensis (Haw.) Berg.. Glycobiology
14: 501-510
[Abstract]
[Full Text]